Geron Corporation (NASDAQ: GERN) is a Healthcare company (Biotechnology) with a market capitalization of $644M. The Maz Rating grades it against the other companies in its sector.
Geron Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $1.00, Geron Corporation trades at 3.0x sales and 3.0x book value. Over the last twelve months it generated about $216M of revenue and a net loss of $45M. It runs a gross margin of 91.6%, an operating margin of -8.2% and a net margin of -23.0%. It shows return on equity of -22.3%, return on invested capital of -3.9% and a free cash flow yield of -14.1%. On the balance sheet: a debt-to-equity ratio of 0.53 and a current ratio of 6.31. Over the past 52 weeks the share price ranged from $0.84 to $2.01, with a beta of 0.61.
Geron Corporation does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 15 Buy and 7 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.